Dietary Selenium Supplementation Does Not Attenuate Mammary Tumorigenesis-Mediated Bone Loss in Male MMTV-PyMT Mice
Bone wasting occurs during the progression of breast cancer and contributes to breast cancer mortality. We evaluated the effect of methylseleninic acid (MSeA), an anti-carcinogenic form of selenium, on bone microstructural changes in the presence of mammary tumors in a male breast cancer model of mouse mammary tumor virus–polyomavirus middle T-antigen (MMTV-PyMT). In this study, we performed microcomputed tomographic analysis of femurs and vertebrae collected from a study showing that dietary supplementation with MSeA reduces mammary tumorigenesis in male mice. Compared to age-matched, non-tumor-bearing mice (MMTV-PyMT negative), the presence of mammary tumors significantly reduced the bone volume fraction, trabecular thickness, and bone mineral density while it increased the structure model index in femurs, but not in vertebrae. Moreover, mammary tumorigenesis decreased plasma concentrations of osteocalcin. Supplementation with MSeA did not affect these changes in MMTV-PyMT mice. In conclusion, mammary tumorigenesis caused bone loss in MMTV-PyMT mice. However, dietary supplementation with MSeA did not attenuate mammary tumor-associated bone loss in this model of male breast cancer.
KeywordsSelenium Mammary tumor Bone loss MMTV-PyMT Male Mice
The authors gratefully acknowledge the assistance of the following staff of the Grand Forks Human Nutrition Research Center: Lana DeMars, Kay Keehr, and Kim Michelsen for technical support, James Lindlauf for preparing experimental diets, and vivarium staff for providing high-quality animal care.
Funding for this work was provided by the USDA, ARS, Research Project 3062-51000-050-00D.
Compliance with Ethical Standards
This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (Institute for Laboratory Animal Research (2011) Guide for the care and use of laboratory animals, 8th edn. National Academies Press, Washington, D.C. https://doi.org/10.17226/12910) and approved by the Institutional Animal Care and Use Committee of the Grand Forks Human Nutrition Research Center.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM, Voogd AC (2006) Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 6:179. https://doi.org/10.1186/1471-2407-6-179 Google Scholar
- 3.Kandarian S (2008) The molecular basis of skeletal muscle atrophy--parallels with osteoporotic signaling. J Musculoskelet Neuronal Interact 8(4):340–341Google Scholar
- 4.Preston T, Fearon KCH, Robertson I, East BW, Calman KC (1987) Tissue loss during severe wasting in lung cancer patients. In: Ellis KJ, Yasumura S, Morgan WD (eds) In vivo body composition studies. Institute Of Physical Sciences in Medicine, London, pp 60–69Google Scholar
- 7.Lockwood K, Moesgaard S, Hanioka T, Folkers K (1994) Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Asp Med 15(Suppl):S231–S240Google Scholar
- 9.Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gail MH, Dong ZW, Yu B, Mark SD, Taylor PR (2009) Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 101(7):507–518. https://doi.org/10.1093/jnci/djp037 Google Scholar
- 10.Ip C, Thompson HJ, Zhu Z, Ganther HE (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60(11):2882–2886Google Scholar
- 13.Molanouri Shamsi M, Chekachak S, Soudi S, Quinn LS, Ranjbar K, Chenari J, Yazdi MH, Mahdavi M (2017) Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10/TNF-alpha ratio in skeletal muscle of 4T1 breast cancer mice with cachexia. Cytokine 90:100–108. https://doi.org/10.1016/j.cyto.2016.11.005 Google Scholar
- 15.Wang H, Chan YL, Li TL, Bauer BA, Hsia S, Wang CH, Huang JS, Wang HM, Yeh KY, Huang TH, Wu GJ, Wu CJ (2013) Reduction of splenic immunosuppressive cells and enhancement of anti-tumor immunity by synergy of fish oil and selenium yeast. PLoS One 8(1):e52912. https://doi.org/10.1371/journal.pone.0052912 Google Scholar
- 18.Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76. https://doi.org/10.1186/gb-2007-8-5-r76 Google Scholar
- 19.Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61(22):8298–8305Google Scholar
- 24.Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, Kanthan R, Maraqa L, Litwiniuk M, Mottolese M, Pollock S, Provenzano E, Quinlan PR, Reall G, Shousha S, Stephens M, Verghese ET, Walker RA, Hanby AM, Speirs V (2012) A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 133(3):949–958. https://doi.org/10.1007/s10549-011-1856-9 Google Scholar
- 28.Yan L, Nielsen FH, Sundaram S, Cao J (2015) High-fat diet enhances and plasminogen activator inhibitor-1 deficiency attenuates bone loss in mice with Lewis lung carcinoma. Anticancer Res 35(7):3839–3847Google Scholar
- 32.Perez EA, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology (Williston Park) 20(9):1029–1039 discussion 1039-1040, 1042, 1048Google Scholar
- 33.Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27. https://doi.org/10.1016/j.jsbmb.2007.03.030 Google Scholar
- 34.Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, Van Den Eeden SK, Wood SN, Falk RT, Parisi D, Guillemette C, Caron P, Turcotte V, Habel LA, Isaacs CJ, Riboli E, Weiderpass E, Cook MB (2015) Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 33(18):2041–2050. https://doi.org/10.1200/JCO.2014.59.1602 Google Scholar
- 36.Kuba S, Ishida M, Oikawa M, Nakamura Y, Yamanouchi K, Tokunaga E, Taguchi K, Esaki T, Eguchi S, Ohno S (2016) Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature. Breast Cancer 23(6):945–949. https://doi.org/10.1007/s12282-016-0679-2 Google Scholar
- 41.Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66(14):7176–7184. https://doi.org/10.1158/0008-5472.CAN-06-0825 Google Scholar
- 48.Ip C, Ganther HE (1990) Activity of methylated forms of selenium in cancer prevention. Cancer Res 50(4):1206–1211Google Scholar
- 49.Ip C, Hayes C, Budnick RM, Ganther HE (1991) Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51(2):595–600Google Scholar
- 51.Ebert R, Ulmer M, Zeck S, Meissner-Weigl J, Schneider D, Stopper H, Schupp N, Kassem M, Jakob F (2006) Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 24(5):1226–1235. https://doi.org/10.1634/stemcells.2005-0117 Google Scholar
- 52.Jakob F, Becker K, Paar E, Ebert-Duemig R, Schutze N (2002) Expression and regulation of thioredoxin reductases and other selenoproteins in bone. Methods Enzymol 347:168–179Google Scholar